Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation
2025 · Gynecologic Oncology · 3 citations
https://doi.org/10.1016/j.ygyno.2025.04.499